Showing results (81-90 of 216) with videos related to

Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|April 21, 2009
Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective studyLi Zhang, Xue Hou, Shun Lu, et al.
Clinical and Translational Medicine|February 19, 2020
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patientsQiufan Zheng, Shaodong Hong, Yan Huang, et al.
The Oncologist|May 4, 2019
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid TumorsYuxiang Ma, Wenfeng Fang, Yang Zhang, et al.
Frontiers in Molecular Biosciences|June 23, 2025
Mitochondrial mass and mitochondrial membrane potential of peripheral lymphocytes: promising biomarkers of systemic lupus erythematosusGuanfei Zhao, Haolong Li, Yutong Miao, et al.
BMC Cancer|July 3, 2024
Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapyShaoyan Lin, Huaqiang Zhou, Gang Chen, et al.
Medicine|January 15, 2016
Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic ChemotherapyZhihuang Hu, Wenhua Liang, Yunpeng Yang, et al.
Molecular Cancer Therapeutics|May 20, 2016
Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex VivoZhen Chen, Yifan Chen, Meng Xu, et al.
Translational Lung Cancer Research|September 21, 2020
PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapyWenfeng Fang, Yihua Huang, Weiguang Gu, et al.
Medicine|August 7, 2016
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institutionXiaobo He, Yang Zhang, Yuxiang Ma, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 27, 2014
A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancerTing Zhou, Shaodong Hong, Zhihuang Hu, et al.
Pageof 22